Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication

被引:7
|
作者
Mueller, N. [1 ]
Lehmann, T. [2 ]
Kloess, A. [4 ]
Guenster, C. [4 ]
Kloos, C. [1 ]
Mueller, U. A. [1 ,3 ]
机构
[1] Jena Univ Hosp, Dept Internal Med 3, Jena, Germany
[2] Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[3] Jena Univ Hosp, Ctr Outpatient Care, Jena, Germany
[4] Res Inst Local Hlth Care Funds, Berlin, Germany
关键词
HOSPITAL ADMISSIONS; CARDIOVASCULAR OUTCOMES; GLYCEMIC CONTROL; RISK-FACTORS; TRENDS; ENGLAND; HBA(1C); INSULIN; ADULTS;
D O I
10.1111/dme.14294
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To investigate the incidence of severe hypoglycaemia over the past 10 years, taking into account changes in anti-hyperglycaemic therapy. Methods This retrospective population-based study used German health insurance data. All adults diagnosed with documented type 2 diabetes (extrapolated to the German population: 6.6 million in 2006; 7.9 million in 2011; 8.86 million in 2016) were screened for severe hypoglycaemia. Anti-hyperglycaemic agents were identified by Anatomical Therapeutic Chemical (ATC) code. Results The event rate for severe hypoglycaemia was 460 per 100 000 people in 2006, 490 per 100 000 in 2011 and 360 per 100 000 in 2016. The proportion of people with severe hypoglycaemia receiving sulfonylureas, as well as receiving combination therapy of metformin and sulfonylureas decreased from 2006 to 2016 (23.6% vs. 6.2%) Among those with severe hypoglycaemia in 2006, there were no prescriptions for dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose co-transporter 2 (SGLT2) agonists. The proportions of people with severe hypoglycaemia receiving DPP-4 inhibitors, GLP-1 receptor agonists or SGLT2 agonists in 2011 and 2016 were low. The proportion of people receiving human insulin also decreased (from 11.3% in 2006 to 10.3% in 2011 and 4.3% in 2016); the proportion of people receiving insulin analogues increased from 5.4% in 2006 to 11.5% in 2016. Therapy with mixed insulins was used by 19.7% of people with severe hypoglycaemia in 2006, by 14.0% in 2011 and by 7.3% in 2016. People undergoing therapy with insulin analogues have the highest risk of severe hypoglycaemia adjusted by age, gender, nephropathy diagnosis and year of survey [odds ratio (OR) 14.4, 95% confidence interval (95% CI) 13.5-15.5]. Conclusion The incidence of severe hypoglycaemic events in Germany increased between 2006 and 2011, and decreased in 2016.
引用
收藏
页码:1326 / 1332
页数:7
相关论文
共 40 条
  • [1] Incidence of severe hypoglycaemia in 2006 and 2011 in consideration of the medication in Germany: analysis based on health insurance data
    Mueller, N.
    Kloos, C.
    Gerste, B.
    Hartmann, M.
    Mueller, U. A.
    [J]. DIABETOLOGIA, 2015, 58 : S461 - S462
  • [2] Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany
    Mueller, N.
    Lehmann, T.
    Gerste, B.
    Adler, J-B
    Kloos, C.
    Hartmann, M.
    Kramer, G.
    Kuniss, N.
    Mueller, U. A.
    [J]. DIABETIC MEDICINE, 2017, 34 (09) : 1212 - 1218
  • [3] Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data
    Mueller, N.
    Heller, T.
    Freitag, M. H.
    Gerste, B.
    Haupt, C. M.
    Wolf, G.
    Mueller, U. A.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 951 - 957
  • [4] Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
    Liu, Shimeng
    Liu, Jing
    Si, Lei
    Ke, Xiong
    Liu, Liu
    Ren, Yanfeng
    Bao, Shiyi
    Li, Fuming
    Yu, Yijiang
    Pan, Qi
    Wei, Yan
    Chen, Yingyao
    [J]. BMJ GLOBAL HEALTH, 2023, 8 (04):
  • [5] Risk of major adverse cardiovascular events, severe hypoglycaemia and all-causemortality forwidely used anti-hyperglycaemic dual and triple therapies in type 2 diabetes
    Jensen, M. H.
    Kjolby, M.
    Hejlesen, O.
    Jakobsen, P.
    Vestergaard, P.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S136 - S136
  • [6] Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages - A Follow-up Analysis of Health Insurance Data from Germany
    Busch, Martin
    Lehmann, Thomas
    Wolf, Gunter
    Guenster, Christian
    Mueller, Ulrich Alfons
    Mueller, Nicolle
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (11) : 821 - +
  • [7] Progression of Heart Failure in People with Type 2 Diabetes in Germany: An Analysis Using German Health Insurance Claims Data
    Lee, Keni Cheng-Siang
    Wagner, Tobias
    Kennedy, Adee
    Wilke, Michael Holger
    [J]. JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 58 - 65
  • [8] Incidence trend of type 2 diabetes from 2012 to 2021 in Germany: an analysis of health claims data of 11 million statutorily insured people
    Lehner, Carolin T.
    Eberl, Marian
    Donnachie, Ewan
    Tanaka, Luana F.
    Schauberger, Gunther
    Schederecker, Florian
    Himmler, Sebastian
    Sundmacher, Leonie
    Klug, Stefanie J.
    [J]. DIABETOLOGIA, 2024, 67 (06) : 1040 - 1050
  • [9] Spatio-Temporal Trends in the Incidence of Type 2 Diabetes in Germany Analysis of the Claims Data of 63 Million Persons With Statutory Health Insurance From 2014 to 2019
    Toennies, Thaddaeus
    Hoyer, Annika
    Brinks, Ralph
    Kuss, Oliver
    Hering, Ramona
    Schulz, Mandy
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (11): : 173 - +
  • [10] Age at diagnosis of Type 2 diabetes in Germany: a nationwide analysis based on claims data from 69 million people
    Jacobs, E.
    Rathmann, W.
    Toennies, T.
    Arendt, D.
    Marchowez, M.
    Veith, L.
    Kuss, O.
    Brinks, R.
    Hoyer, A.
    [J]. DIABETIC MEDICINE, 2020, 37 (10) : 1723 - 1727